1 June 2017 - American taxpayers may have overpaid for Mylan's EpiPen shot by as much as $US1.27 billion ($1.71 billion) over the last decade, according to a US government report.

Senator Charles Grassley, a Republican politician from Iowa, on Wednesday posted a copy of a report by the Department of Health and Human Services' Office of the Inspector General.

The report says that Mylan, by classifying the life-saving allergy shot as a generic drug rather than a brand-name product, shortchanged the Medicaid program for the poor.

Read Sydney Morning Herald article